Virbac SA (VRBCF)
USD 339.23
(0.0%)
USD 339.23
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -54.63 Million EUR | 37.19% |
| 2022 | -86.98 Million EUR | -11.07% |
| 2021 | -78.32 Million EUR | -17.79% |
| 2020 | -66.49 Million EUR | -118.19% |
| 2019 | 365.59 Million EUR | -13.75% |
| 2018 | 423.9 Million EUR | -7.42% |
| 2017 | 457.89 Million EUR | -15.56% |
| 2016 | 542.25 Million EUR | -10.04% |
| 2015 | 602.79 Million EUR | 210.18% |
| 2014 | 194.33 Million EUR | 7.86% |
| 2013 | 180.17 Million EUR | 36.61% |
| 2012 | 131.89 Million EUR | 94.08% |
| 2011 | 67.95 Million EUR | 2077.41% |
| 2010 | 3.12 Million EUR | -90.78% |
| 2009 | 33.84 Million EUR | 502.19% |
| 2008 | -8.41 Million EUR | 15.36% |
| 2007 | -9.94 Million EUR | -114.8% |
| 2006 | 67.18 Million EUR | 359.92% |
| 2005 | 14.6 Million EUR | -61.24% |
| 2004 | 37.68 Million EUR | -37.98% |
| 2003 | 60.76 Million EUR | 28.9% |
| 2002 | 47.14 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 213.09 Million EUR | 490.01% |
| 2024 Q2 | 213.09 Million EUR | 17.38% |
| 2023 Q1 | -61.81 Million EUR | 28.94% |
| 2023 Q4 | -54.63 Million EUR | 14.29% |
| 2023 Q3 | -63.74 Million EUR | -15.48% |
| 2023 Q2 | -55.19 Million EUR | 10.7% |
| 2023 FY | -54.63 Million EUR | 37.19% |
| 2022 Q4 | -86.98 Million EUR | 3.28% |
| 2022 Q1 | -29.85 Million EUR | 61.88% |
| 2022 FY | -86.98 Million EUR | -11.07% |
| 2022 Q2 | -27.42 Million EUR | 8.13% |
| 2022 Q3 | -89.93 Million EUR | -227.94% |
| 2021 FY | -78.32 Million EUR | -17.79% |
| 2021 Q1 | -63.8 Million EUR | 4.05% |
| 2021 Q3 | -83.75 Million EUR | -46.15% |
| 2021 Q4 | -78.32 Million EUR | 6.49% |
| 2021 Q2 | -57.31 Million EUR | 10.17% |
| 2020 FY | -66.49 Million EUR | -118.19% |
| 2020 Q2 | 344.23 Million EUR | 1.33% |
| 2020 Q4 | -66.49 Million EUR | 7.94% |
| 2020 Q1 | 339.73 Million EUR | -7.07% |
| 2020 Q3 | -72.22 Million EUR | -120.98% |
| 2019 Q4 | 365.59 Million EUR | 1.78% |
| 2019 Q2 | 452.85 Million EUR | 1.42% |
| 2019 Q3 | 359.2 Million EUR | -20.68% |
| 2019 Q1 | 446.51 Million EUR | 5.34% |
| 2019 FY | 365.59 Million EUR | -13.75% |
| 2018 Q3 | 424.38 Million EUR | -12.61% |
| 2018 Q1 | 485.37 Million EUR | 6.0% |
| 2018 FY | 423.9 Million EUR | -7.42% |
| 2018 Q4 | 423.9 Million EUR | -0.11% |
| 2018 Q2 | 485.63 Million EUR | 0.05% |
| 2017 Q4 | 457.89 Million EUR | 0.14% |
| 2017 FY | 457.89 Million EUR | -15.56% |
| 2017 Q2 | 540.75 Million EUR | 0.25% |
| 2017 Q1 | 539.39 Million EUR | -0.53% |
| 2017 Q3 | 457.26 Million EUR | -15.44% |
| 2016 Q1 | 603.63 Million EUR | 0.14% |
| 2016 FY | 542.25 Million EUR | -10.04% |
| 2016 Q4 | 542.25 Million EUR | 0.15% |
| 2016 Q3 | 541.43 Million EUR | -9.71% |
| 2016 Q2 | 599.66 Million EUR | -0.66% |
| 2015 FY | 602.79 Million EUR | 210.18% |
| 2015 Q4 | 602.79 Million EUR | 0.06% |
| 2015 Q1 | 630.31 Million EUR | 224.34% |
| 2015 Q3 | 602.44 Million EUR | -3.65% |
| 2015 Q2 | 625.3 Million EUR | -0.79% |
| 2014 Q3 | 196.27 Million EUR | -26.72% |
| 2014 Q1 | 266.59 Million EUR | 47.97% |
| 2014 FY | 194.33 Million EUR | 7.86% |
| 2014 Q4 | 194.33 Million EUR | -0.99% |
| 2014 Q2 | 267.84 Million EUR | 0.47% |
| 2013 FY | 180.17 Million EUR | 36.61% |
| 2013 Q4 | 180.17 Million EUR | 0.98% |
| 2013 Q3 | 178.43 Million EUR | -16.53% |
| 2013 Q2 | 213.76 Million EUR | 0.32% |
| 2013 Q1 | 213.09 Million EUR | 61.57% |
| 2012 FY | 131.89 Million EUR | 94.08% |
| 2012 Q4 | 131.89 Million EUR | 0.0% |
| 2012 Q2 | -41.34 Million EUR | 0.0% |
| 2011 Q2 | 6.79 Million EUR | 0.0% |
| 2011 Q4 | 67.95 Million EUR | 0.0% |
| 2011 FY | 67.95 Million EUR | 2077.41% |
| 2010 FY | 3.12 Million EUR | -90.78% |
| 2010 Q2 | 37.99 Million EUR | 0.0% |
| 2010 Q4 | 3.12 Million EUR | 0.0% |
| 2009 Q4 | 33.84 Million EUR | 0.0% |
| 2009 FY | 33.84 Million EUR | 502.19% |
| 2008 FY | -8.41 Million EUR | 15.36% |
| 2007 FY | -9.94 Million EUR | -114.8% |
| 2006 FY | 67.18 Million EUR | 359.92% |
| 2005 FY | 14.6 Million EUR | -61.24% |
| 2004 FY | 37.68 Million EUR | -37.98% |
| 2003 FY | 60.76 Million EUR | 28.9% |
| 2002 FY | 47.14 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.74 Billion USD | 100.24% |
| Bristol-Myers Squibb Company PFD CONV 2 | 30 Billion USD | 100.182% |
| CSPC Pharmaceutical Group Limited | -1.59 Billion USD | 96.572% |
| Clarus Therapeutics Holdings, Inc. | 15.85 Million USD | 444.639% |
| Novartis AG | 12.95 Billion USD | 100.422% |
| PT Kalbe Farma Tbk. | -169.7 Million USD | 67.803% |